|
End-of-day quote
Mexican S.E.
2026-08-25
|
5-day change | 1st Jan Change | ||
| 2,520.00 MXN | +1.82% |
|
+5.52% | +13.40% |
| 08-25 | Wall Street Wants Receipts |  |
| 08-25 | Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 1,315.04 | +6.6% | 29 | ||||||
| 272.5 | -0.23% | 22 | ||||||
| 276.59 | +4.06% | 29 | ||||||
| 370.31 | -0.93% | 18 | ||||||
| 154.32 | -3.45% | 21 | ||||||
| 212.3 | +24.8% | 22 | ||||||
| 388.48 | -12.16% | 29 | ||||||
| 310.82 | +0.98% | 23 | ||||||
| 157.41 | +5.81% | 27 | ||||||
| 28.61 | +0.13% | 26 | ||||||
| 563.12 | +1.86% | 25 | ||||||
| 66.21 | -2.52% | 24 | ||||||
| 94.28 | +19.73% | 23 | ||||||
| 21.69 | +13.82% | 20 | ||||||
| 9,350 | +34.53% | 15 | ||||||
| 6,515.81 | +12.09% | 16 | ||||||
| 56.83 | +15.37% | 18 | ||||||
| 71.74 | +54.31% | 17 | ||||||
| 4.214 | +14.02% | 17 | ||||||
| Average | 1,064.75 | +9.94% | 22 | ||||||
| Weighted average by Cap. | 706.78 | +4.90% | 24 |
- Stock Market
- Stocks
- GILD Stock
- GILD * Stock
- Sector Gilead Sciences, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
